FDA’s Høeg plans to scrutinize SSRIs, RSV shots for babies
Tracy Beth Høeg, the head of the Food and Drug Administration’s drug regulatory department, recently addressed her staff and highlighted her focus on evaluating the safety of antidepressants used by pregnant women and monoclonal antibodies that protect infants from respiratory syncytial virus (RSV).
During her speech, Høeg emphasized the need for comprehensive safety monitoring of these products during pregnancy, noting that there is room for improvement in this area. She expressed excitement about the agreement among the staff at the Center for Drug Evaluation and Research (CDER) regarding the importance of enhancing safety monitoring for these medications.
Høeg’s interest in evaluating the safety of antidepressants and RSV antibodies stems from her previous work in these areas. She is committed to ensuring that thorough safety assessments are conducted to protect the health and well-being of pregnant women and infants.
The FDA plays a crucial role in overseeing the safety and effectiveness of medications, and Høeg’s priorities reflect the agency’s ongoing commitment to upholding rigorous standards in drug regulation. By focusing on these key issues, she aims to enhance the agency’s ability to safeguard public health and promote the responsible use of medications.
As the top drug regulator at the FDA, Høeg’s leadership will be instrumental in guiding the agency’s efforts to address emerging safety concerns and enhance the monitoring of medications used by vulnerable populations. Her dedication to promoting safety and transparency in drug regulation will help ensure that patients receive the highest quality care and protection.
For more in-depth analysis and exclusive content on this topic, subscribers can access additional information through STAT+. Subscribing to STAT+ provides access to premium events, newsletters, news alerts, and exclusive articles like this one. Subscribe now to stay informed on the latest developments in drug regulation and healthcare.
